Phenotype and course of Hutchinson-Gilford progeria syndrome
- PMID: 18256394
- PMCID: PMC2940940
- DOI: 10.1056/NEJMoa0706898
Phenotype and course of Hutchinson-Gilford progeria syndrome
Abstract
Background: Hutchinson-Gilford progeria syndrome is a rare, sporadic, autosomal dominant syndrome that involves premature aging, generally leading to death at approximately 13 years of age due to myocardial infarction or stroke. The genetic basis of most cases of this syndrome is a change from glycine GGC to glycine GGT in codon 608 of the lamin A (LMNA) gene, which activates a cryptic splice donor site to produce abnormal lamin A; this disrupts the nuclear membrane and alters transcription.
Methods: We enrolled 15 children between 1 and 17 years of age, representing nearly half of the world's known patients with Hutchinson-Gilford progeria syndrome, in a comprehensive clinical protocol between February 2005 and May 2006.
Results: Clinical investigations confirmed sclerotic skin, joint contractures, bone abnormalities, alopecia, and growth impairment in all 15 patients; cardiovascular and central nervous system sequelae were also documented. Previously unrecognized findings included prolonged prothrombin times, elevated platelet counts and serum phosphorus levels, measured reductions in joint range of motion, low-frequency conductive hearing loss, and functional oral deficits. Growth impairment was not related to inadequate nutrition, insulin unresponsiveness, or growth hormone deficiency. Growth hormone treatment in a few patients increased height growth by 10% and weight growth by 50%. Cardiovascular studies revealed diminishing vascular function with age, including elevated blood pressure, reduced vascular compliance, decreased ankle-brachial indexes, and adventitial thickening.
Conclusions: Establishing the detailed phenotype of Hutchinson-Gilford progeria syndrome is important because advances in understanding this syndrome may offer insight into normal aging. Abnormal lamin A (progerin) appears to accumulate with aging in normal cells. (ClinicalTrials.gov number, NCT00094393.)
Copyright 2008 Massachusetts Medical Society.
Figures
Comment in
-
Hutchinson-Gilford progeria syndrome, aging, and the nuclear lamina.N Engl J Med. 2008 Feb 7;358(6):552-5. doi: 10.1056/NEJMp0800071. N Engl J Med. 2008. PMID: 18256390 No abstract available.
-
Hutchinson-Gilford progeria syndrome.N Engl J Med. 2008 May 29;358(22):2409-10; author reply 2410-1. doi: 10.1056/NEJMc086092. N Engl J Med. 2008. PMID: 18509130 Free PMC article. No abstract available.
-
Hutchinson-Gilford progeria syndrome.N Engl J Med. 2008 May 29;358(22):2410; author reply 2410-1. N Engl J Med. 2008. PMID: 18512277 No abstract available.
Similar articles
-
Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.J Proteomics. 2013 Oct 8;91:466-77. doi: 10.1016/j.jprot.2013.08.008. Epub 2013 Aug 20. J Proteomics. 2013. PMID: 23969228
-
Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome.Hypertension. 2012 Jan;59(1):92-7. doi: 10.1161/HYPERTENSIONAHA.111.180919. Epub 2011 Nov 14. Hypertension. 2012. PMID: 22083160 Free PMC article. Clinical Trial.
-
Hutchinson-Gilford progeria syndrome: review of the phenotype.Am J Med Genet A. 2006 Dec 1;140(23):2603-24. doi: 10.1002/ajmg.a.31346. Am J Med Genet A. 2006. PMID: 16838330 Review.
-
Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.Med Hypotheses. 2018 Sep;118:151-162. doi: 10.1016/j.mehy.2018.06.029. Epub 2018 Jun 28. Med Hypotheses. 2018. PMID: 30037605
-
Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach.Recent Pat Biotechnol. 2021;15(4):266-285. doi: 10.2174/1872208315666210928114720. Recent Pat Biotechnol. 2021. PMID: 34602042 Review.
Cited by
-
Characterization of the craniofacial abnormalities of the homozygous G608G progeria mouse model.Front Physiol. 2024 Nov 6;15:1481985. doi: 10.3389/fphys.2024.1481985. eCollection 2024. Front Physiol. 2024. PMID: 39568542 Free PMC article.
-
Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome.Commun Biol. 2024 Oct 26;7(1):1398. doi: 10.1038/s42003-024-06967-z. Commun Biol. 2024. PMID: 39462037 Free PMC article.
-
Enhancing Cellular Homeostasis: Targeted Botanical Compounds Boost Cellular Health Functions in Normal and Premature Aging Fibroblasts.Biomolecules. 2024 Oct 16;14(10):1310. doi: 10.3390/biom14101310. Biomolecules. 2024. PMID: 39456243 Free PMC article.
-
The syntaxin-binding protein STXBP5 regulates progerin expression.Sci Rep. 2024 Oct 8;14(1):23376. doi: 10.1038/s41598-024-74621-z. Sci Rep. 2024. PMID: 39379476 Free PMC article.
-
Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome.J Clin Invest. 2024 Oct 1;134(22):e173448. doi: 10.1172/JCI173448. J Clin Invest. 2024. PMID: 39352768 Free PMC article.
References
-
- DeBusk FL. The Hutchinson-Gilford progeria syndrome: report of 4 cases and review of the literature. J Pediatr. 1972;80:697–724. - PubMed
-
- Hutchison CJ. Lamins: building blocks or regulators of gene expression? Nat Rev Mol Cell Biol. 2002;3:848–58. - PubMed
-
- Hennekam RCM. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. 2006;140:2603–24. - PubMed
-
- De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin A truncation in Hutchinson-Gilford progeria. Science. 2003;300:2055. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous